All News
2022 Memorium
Sadly, too many of our rheumatology colleagues passed on in 2022. Here is an (incomplete) list of notable brethren, mentors, do-gooders and great rheumatologists:
Read Article
2022 Rheumatology Year in Review (1-6-2023)
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
Read Article
2022 Rheumatology Year in Review
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Read Article
ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis
The American College of Physicians (ACP) has issued an update of its guideline with clinical recommendations for treatments of primary osteoporosis and low bone mass in adults.
Read Article
2022 Match - Strong Appeal of Adult Rheumatology, Less So in Pediatric Rheumatology
The American College of Rheumatology is pleased to announce another successful recruitment season and welcomes this impressive pool of applicants to the field of rheumatology.
Read Article
Extreme Global Costs of Physical Inactivity
A global, population-based study shows that physical inactivity is not only an important modifiable risk factor for non-communicable diseases (NCDs) and mental health conditions, it also imparts a considerable health and economic burden that is avoidable.
Read Article
Best of 2022: Emerging Therapeutics for Lupus
Impressive data on novel treatment for SLE were presented at the EULAR22 Congress. A disease that is difficult to study due to its pleomorphic presentation, unpredictable disease course, and high mortality rates, SLE is considered the dragon of all autoimmune diseases. Here are highlights of four exciting abstracts presented at the meeting with emerging therapeutics designed to slay the beast.
Read Article
Best of 2022: Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines
In the wake of the 2016 AAOS Guidelines, rheumatologists dutifully reduced the dose HCQ take by patients with SLE to some number south of 5mg/kg per day. Though I believe the ophthalmologists correctly interpreted a 2014 paper in JAMA Ophthalmology that quoted a much-higher rate of HCQ associated retinopathy than had previously been appreciated, they and subsequent guidelines published in the field of rheumatology lacked a critical piece of information: what actually happens when you do this?
Read Article
Best of 2022: EULAR 2022 Top 10 Abstracts
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media…
Read Article
Best of 2022: ACR/EULAR 2022 Classification Criteria for Granulomatosis with Polyangiitis
The ACR/EULAR 2022 revised classification criteria for granulomatosis with polyangiitis (GPA) have been updated with performance characteristics and are validated for use in clinical research.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
